Grazoprevir

Contraindicated

Grazoprevir Cyclosporine Injection Atopica Increased grazoprevir exposure and an increased risk of ALT elevation Details Grazoprevir Cyclosporine Ophthalmic Cequa Increased grazoprevir exposure and an increased risk of ALT elevation Details Grazoprevir Darolutamide Nubeqa Increased grazoprevir exposure and an increased risk of ALT elevation Details Grazoprevir Enasidenib Idhifa Increased grazoprevir exposure and an increased risk of ALT elevation Details Grazoprevir Fostemsavir Rukobia Increased grazoprevir exposure and increased risk of ALT elevations Details Grazoprevir Gemfibrozil Lopid Increased grazoprevir exposure and an increased risk of ALT elevation Details Grazoprevir Ketoconazole Topical Extina® Foam Increased grazoprevir exposure Details

Major

Grazoprevir Abametapir Explained Increased exposure of CYP3A4 substrate Details Grazoprevir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Grazoprevir Atogepant Qulipta Increased atogepant exposure Details Grazoprevir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Grazoprevir Eluxadoline Viberzi Increased eluxadoline exposure Details Grazoprevir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Grazoprevir Leflunomide Arava Increased exposure of OATP1B1/1B3 substrate Details Grazoprevir Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Grazoprevir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Grazoprevir Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Grazoprevir Methylergonovine Methergine Increased methylergonovine exposure Details Grazoprevir Midostaurin Rydapt Increased OATP1B1 substrate exposure Details Grazoprevir Nafcillin Injection Unipen® Injection Decreased grazoprevir plasma concentrations and reduced grazoprevir efficacy Details Grazoprevir Nifedipine Adalat® Increased NIFEdipine exposure Details

Moderate

Grazoprevir Simvastatin Flolipid Explained Increased statin plasma concentrations Details Grazoprevir Dofetilide Tikosyn Increased dofetilide exposure Details Grazoprevir Encorafenib Braftovi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Grazoprevir Fluvastatin Lescol Increased statin plasma concentrations Details Grazoprevir Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Grazoprevir Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Grazoprevir Lovastatin Altocor® Increased statin plasma concentrations Details